Bevacizumab and oral metronomic cyclophosphamide in platinum-resistant ovarian cancer
about
Outcomes of advanced epithelial ovarian cancer with integration of metronomic chemotherapy: An Indian rural cancer centre experience.Quality of life in patients with metastatic breast cancer treated with metronomic chemotherapy.Clinical response in patients with ovarian cancer treated with metronomic chemotherapy.
P2860
Bevacizumab and oral metronomic cyclophosphamide in platinum-resistant ovarian cancer
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 July 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Bevacizumab and oral metronomic cyclophosphamide in platinum-resistant ovarian cancer
@en
Bevacizumab and oral metronomic cyclophosphamide in platinum-resistant ovarian cancer.
@nl
type
label
Bevacizumab and oral metronomic cyclophosphamide in platinum-resistant ovarian cancer
@en
Bevacizumab and oral metronomic cyclophosphamide in platinum-resistant ovarian cancer.
@nl
prefLabel
Bevacizumab and oral metronomic cyclophosphamide in platinum-resistant ovarian cancer
@en
Bevacizumab and oral metronomic cyclophosphamide in platinum-resistant ovarian cancer.
@nl
P2860
P1476
Bevacizumab and oral metronomic cyclophosphamide in platinum-resistant ovarian cancer
@en
P2860
P304
P356
10.3802/JGO.2013.24.3.209
P577
2013-07-04T00:00:00Z